Can-Fite BioPharma (CANF) EBIT (2014 - 2023)

Can-Fite BioPharma (CANF) has 10 years of EBIT data on file, last reported at -$1.8 million in Q4 2023.

• For the quarter ending Q4 2023, EBIT fell 55.16% year-over-year to -$1.8 million; the trailing twelve-month figure through Dec 2023 stood at -$8.2 million (changed 0.0% YoY), and the FY2025 full-year result was -$10.0 million, down 22.39% from the prior year.
• EBIT was -$1.8 million for Q4 2023 at Can-Fite BioPharma, up from -$1.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $1.7 million in Q1 2019 to a low of -$6.3 million in Q2 2019.
• A 5-year average of -$2.7 million and a median of -$2.6 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT tumbled 533.39% in 2019 and jumped 70.66% in 2022, its largest moves.
• Can-Fite BioPharma's EBIT stood at -$4.6 million in 2019, then grew by 22.95% to -$3.6 million in 2020, then dropped by 13.37% to -$4.0 million in 2021, then soared by 70.66% to -$1.2 million in 2022, then sank by 55.16% to -$1.8 million in 2023.
• Per Business Quant data, the three most recent EBIT figures were -$1.8 million in Q4 2023, -$1.9 million in Q3 2023, and -$1.8 million in Q2 2023.